NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04675450 |
|
Recruitment Status :
Not yet recruiting
First Posted : December 19, 2020
Last Update Posted : October 14, 2022
|
Sponsor:
Conjupro Biotherapeutics, Inc.
Collaborator:
CSPC-NBP Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Conjupro Biotherapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | December 30, 2024 |
| Estimated Study Completion Date : | January 30, 2025 |